View:
-------------------------------------------
OMB APPROVAL
-------------------------------------------
OMB Number:
Expires:
Estimated average burden
hours per form...................
-------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.____________)*
Healthcore Medical Solutions, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Class A Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
42220B101
- --------------------------------------------------------------------------------
(CUSIP Number)
Adam D. Eilenberg
Ehrenreich Eilenberg Krause & Zivian LLP
11 East 44th Street, 17th Floor
New York, N.Y. 10017
(212) 986-9700
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 1, 1998
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement of Schedule 13G to report
the acquisition which is the subject of the Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
CUSIP No. 42220B101 13D
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SIGA Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DE
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 300,800 (including 149,800 Warrants
SHARES exercisable at $6.50 per share)
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 300,800 (including 149,800 Warrants
exercisable at $6.50 per share)
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
300,800 (including 149,800 Warrants exercisable at $6.50 per share)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.003% (taking into account only shares of Common Stock; 9.50% if also
including 149,800 Warrants exercisable at $6.50 per share)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 42220B101 13D
Schedule 13D
Item 1. Security and Issuer
This statement relates to the Class A Common Stock, $.01 par value ("Common
Stock"), of Healthcore Medical Solutions, Inc. (the "Issuer"), which has its
principal executive office at 11904 Blue Ridge Boulevard, Grandview, MO 64030.
Item 2. Identity and Background
The Reporting Person is SIGA Pharmaceuticals, Inc., a development stage
biopharmaceutical company incorporated in Delaware, with an address of 420
Lexington Avenue, New York, NY 10170. During the last five years, the Reporting
Person has not been (i) convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors); or (ii) a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.
Item 3. Source of Funds or Other Consideration
The Reporting Person acquired an aggregate of 1,200 shares of Common Stock at a
price of $.875 and $1.16 and 149,800 units ("Units"), each Unit consisting of
one share of Common Stock and one currently exercisable Warrant (the "Warrants")
to purchase one share of Common Stock (at an exercise price of $6.50 per share),
in several open market purchases from September 11, 1998 through October 15,
1998 at an average purchase price of $ 1.11 per Unit. The Reporting Person used
its working capital to effect the purchases.
The Reporting Person currently holds 151,000 shares of Common Stock, which
represents 5.003% of the class of Common Stock. The Reporting Person also holds
149,800 Warrants that are included in the Units, which are currently
exercisable, even though the exercise price of the Warrants is substantially in
excess of the current market price for the Common Stock. The Reporting Person
currently has no intention of exercising any of the Warrants. If the shares of
Common Stock issuable upon exercise of the Warrants are included with the shares
of Common Stock currently held by the Reporting Person, as provided in Rule
13(d)-(3)(d) under the Securities Exchange Act of 1934, as amended, the
percentage of the entire class of Common Stock beneficially held by the
Reporting Person is 9.50%.
Item 4. Purpose of Transaction
The Reporting Person acquired the shares of Common Stock and the Units for
investment purposes. The Reporting Person intends to request a meeting with
management and/or representatives of the Board of Directors of the Issuer for
the purpose of discussing methods of maximizing or enhancing shareholder value.
While the Reporting Person has no present intention to purchase any additional
shares of Common Stock or Units, it may, depending upon its evaluation of the
Issuer's business and prospects, determine to increase or decrease or dispose of
its position in the Issuer. In making any such determination, the Reporting
Person will also take into consideration other available business opportunities
and general economic conditions.
Item 5. Interest in Securities of the Issuer
See Items 7 through 13 of the Schedule 13D cover page.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
None.
Item 7. Materials to be Filed as Exhibits.
None.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: October 15, 1998
SIGA PHARMACEUTICALS, INC.
By: /s/ JUDSON A. COOPER
----------------------------------
Name: Judson A. Cooper
Title: Chairman of the Board